Cipla USA Initiates Nationwide Class II Recall of Lanthanum Carbonate Chewable Tablets Due to Quality Failures
Cipla USA, Inc. has initiated a Class II recall (D-0043-2025) for 1,875 boxes of Lanthanum Carbonate Chewable Tablets, 1000mg, distributed nationwide. The recall, stemming from complaints of crushed and broken tablets, highlights critical quality control vulnerabilities. This event demands immediate attention from procurement and supply chain leaders to assess inventory risks and ensure patient safety.
FDA Class II Recall: Cipla USA's Lanthanum Carbonate Chewable Tablets Face Quality Breach
Cipla USA, Inc., operating from Warren, NJ, United States, has initiated a voluntary Class II recall, designated D-0043-2025, for its Lanthanum Carbonate Chewable Tablets, 1000mg. This critical action, reported on November 20, 2024, and classified by the FDA on November 12, 2024, directly impacts the availability and integrity of a vital medication. The recall specifically targets Lot # NB240316, with an expiration date of December 31, 2025, distributed in 10-count bottles under NDC 69097-0936-98. A total of 1,875 boxes, encompassing both Cipla and Exlan branded products, are affected across the USA nationwide distribution network. The primary reason for this recall is a failure in tablet/capsule specifications, specifically, numerous complaints of crushed and broken tablets. For procurement directors, this necessitates an immediate audit of current inventory to identify and quarantine any affected lots, preventing further distribution of compromised product. Regulatory affairs heads must assess the immediate patient safety implications of compromised dosage forms and prepare for potential inquiries. Supply chain VPs need to understand the scope of product removal from the U.S. market and its potential impact on patient access to this critical phosphate binder.
Commercial and Supply Chain Vulnerabilities Exposed by Lanthanum Carbonate Recall
The nationwide distribution of Cipla USA's recalled Lanthanum Carbonate Chewable Tablets, 1000mg, highlights significant commercial and supply chain vulnerabilities for companies relying on third-party manufacturers or distributors. Lanthanum Carbonate is a critical medication for managing hyperphosphatemia in patients with end-stage renal disease, making any disruption a serious concern for patient care. The reported issue of crushed and broken tablets points to potential deficiencies in manufacturing processes, packaging integrity, or handling during distribution. For procurement directors, this event underscores the imperative for stringent supplier qualification processes, particularly for solid dosage forms where physical integrity is paramount. It mandates a re-evaluation of quality agreements to ensure they include robust provisions for product stability and handling. Supply chain VPs must now assess their risk exposure across all critical drug products, considering the potential for similar quality failures from other suppliers. Business development executives should monitor the market closely, as sustained supply issues could create opportunities for alternative manufacturers or distributors capable of demonstrating superior product quality and supply chain resilience. The recall's Class II classification indicates that the use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote, but the commercial and reputational damage can be substantial.
Regulatory Compliance and Remediation for Cipla USA Following Quality Lapses
Cipla USA, Inc.'s voluntary initiation of this Class II recall demonstrates a firm-level recognition of a product quality issue, a factor the FDA considers in its oversight. However, the 'Ongoing' status of recall D-0043-2025 means that the FDA continues to monitor the effectiveness of the recall and the firm's corrective actions. Regulatory affairs heads must recognize that while voluntary, the FDA expects a thorough investigation into the root cause of the crushed and broken tablets. This includes assessing manufacturing controls, packaging materials, and distribution handling protocols at the facility responsible for production, even if manufactured for Cipla USA. The company will be required to implement comprehensive corrective and preventive actions (CAPA) to address these deficiencies and prevent recurrence. For procurement teams, engaging with Cipla USA to understand their remediation plan is crucial for evaluating future supply reliability and ensuring that any resumed supply meets stringent quality standards. This incident serves as a stark reminder for all industry stakeholders that continuous monitoring of supplier quality metrics, adherence to Good Manufacturing Practices (GMP), and robust post-market surveillance are non-negotiable. Failure to effectively remediate and demonstrate sustained compliance could lead to heightened regulatory scrutiny, including potential future Warning Letters or further enforcement actions impacting market access for other products.